Showing results (181-190 of 234) with videos related to

Sort By:
Pageof 24
Gene Therapy|March 19, 2010
Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategyI Y Chen, O Gheysens, S Ray, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2026
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 29, 2008
Multimodal evaluation of in vivo magnetic resonance imaging of myocardial restoration by mouse embryonic stem cellsStephen L Hendry, Koen E A van der Bogt, Ahmad Y Sheikh, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 2, 2007
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failureAhmad Y Sheikh, Hyung J Chun, Alexander J Glassford, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 1, 2020
Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?T S Lewis, J A Kennedy, G J Price, et al.
Nano Letters|January 1, 2020
Slippery and Wear-Resistant Surfaces Enabled by Interface Engineered GrapheneNeeraj Dwivedi, Tarak Patra, Jae-Bok Lee, et al.
Journal of Hepatology|December 31, 2019
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosisStephen A Harrison, Zachary Goodman, Abdul Jabbar, et al.
Journal of Clinical and Translational Hepatology|May 9, 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory ScienceYasser Fouad, Melissa Palmer, Minjun Chen, et al.
Pageof 24